- Home
- TONX vs ATAI Comparison
TONX vs ATAI Comparison
Compare TONX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TONX
- ATAI
- Stock Information
- Founded
- TONX N/A
- ATAI 2018
- Country
- TONX United States
- ATAI Germany
- Employees
- TONX 23
- ATAI N/A
- Industry
- TONX Other Consumer Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- TONX Consumer Discretionary
- ATAI Health Care
- Exchange
- TONX Nasdaq
- ATAI Nasdaq
- Market Cap
- TONX 442.1M
- ATAI 444.7M
- IPO Year
- TONX N/A
- ATAI 2021
- Fundamental
- Price
- TONX N/A
- ATAI $4.63
- Analyst Decision
- TONX
- ATAI Strong Buy
- Analyst Count
- TONX 0
- ATAI 3
- Target Price
- TONX N/A
- ATAI $13.33
- AVG Volume (30 Days)
- TONX 687.0K
- ATAI 5.1M
- Earning Date
- TONX 11-04-2025
- ATAI 11-12-2025
- Dividend Yield
- TONX N/A
- ATAI N/A
- EPS Growth
- TONX N/A
- ATAI N/A
- EPS
- TONX N/A
- ATAI N/A
- Revenue
- TONX $4,279,000.00
- ATAI $2,309,000.00
- Revenue This Year
- TONX $526.82
- ATAI $661.36
- Revenue Next Year
- TONX $45.45
- ATAI N/A
- P/E Ratio
- TONX N/A
- ATAI N/A
- Revenue Growth
- TONX 4095.10
- ATAI 510.85
- 52 Week Low
- TONX $7.17
- ATAI $1.03
- 52 Week High
- TONX $13.90
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- TONX N/A
- ATAI 59.05
- Support Level
- TONX N/A
- ATAI $4.50
- Resistance Level
- TONX N/A
- ATAI $4.99
- Average True Range (ATR)
- TONX 0.00
- ATAI 0.35
- MACD
- TONX 0.00
- ATAI -0.04
- Stochastic Oscillator
- TONX 0.00
- ATAI 36.32
About TONX TON Strategy Company Common Stock
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.